As it prepares for Phase 3 trials for diabetes treatment, vTv Therapeutics reports $19.2M net loss in FY 2022
High Point biopharmaceutical company vTv Therapeutics is hoping to turn things around under new leadership and with its its lead product – an oral treatment for Type 1 Diabetes – heading into Phase 3 clinical trials.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Lillian Johnson Source Type: news
More News: Biotechnology | Clinical Trials | Diabetes | Diabetes Type 1 | Endocrinology | Health Management